Literature DB >> 34151693

Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.

Sumeet Mirgh1, Archana Sharma2, Bhaarat Folbs2, Vishvdeep Khushoo2, Jyotsna Kapoor2, Narender Tejwani2, Rayaz Ahmed2, Narendra Agrawal2, Partha S Choudhary3, Pallavi Mehta2, Dinesh Bhurani2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34151693     DOI： 10.1080/10428194.2021.1941938

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Elodie Bôle-Richard; Naveen Pemmaraju; Blandine Caël; Etienne Daguindau; Andrew A Lane
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

2.  Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.

Authors:  Harpreet Virk; Sonia Rana; Praveen Sharma; Parveen Lata Bose; Diksha Dev Yadav; Man Updesh Singh Sachdeva; Neelam Varma; Amita Trehan; Deepesh Lad; Alka Rani Khadwal; Pankaj Malhotra; Sreejesh Sreedharanunni
Journal:  Ann Hematol       Date:  2021-06-22       Impact factor: 3.673

Review 3.  Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Yumeng Zhang; Lubomir Sokol
Journal:  Cancer Manag Res       Date:  2022-06-28       Impact factor: 3.602

Review 4.  Conventional Therapeutics in BPDCN Patients-Do They Still Have a Place in the Era of Targeted Therapies?

Authors:  Margaux Poussard; Fanny Angelot-Delettre; Eric Deconinck
Journal:  Cancers (Basel)       Date:  2022-08-02       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.